Company Participants Matt Ferguson - Chief Financial Officer Operator Elutia, Inc. (NASDAQ:ELUT) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Randy Mills - President and Chief Executive Officer Ross Osborn - Cantor Fitzgerald Greetings. Welcome to the Elutia Q3 2023 Financial Results Call. [Operator Instructions]. Please note this conference is being recorded. David Carey Before we begin, I would like to remind you that management will make statements during this call that include forward-lo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39577 Elutia Inc. (Exact name of registrant as specified in its charter) Delaware 47-4790334 (State or other jurisdiction o ...

Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference call is being recorde ...

Forward-Looking Statements This presentation may also contain statistical data, estimates and/or other information or data made by independent parties and/or by us relating to market size and growth, as well about our industry and business. Any such data or information that is based on estimates, forecasts, projections, market research, or similar methodologies, involve a number of assumptions and limitations and are inherently subject to uncertainties, and we have not independently verified the accuracy or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39577 Aziyo Biologics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4790334 (State or other jurisdict ...

Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Â Matt Steinberg - Investor Relations Matt Ferguson - Chief Financial Officer Ross Osborn - Cantor Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that todayÂ's conference call is being recorded. I would now like to hand the conference call over to Matt Steinberg, Finn Partners. Thank you, operator, and thank you ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39577 Aziyo Biologics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4790334 (State or other jurisdic ...

Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Matt Steinberg Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the SEC, including the Aziyo's annual report on Form 10-K for the year ended December 31, 2022 to be filed with the SEC, accessible on the SEC's website at www.sec.gov. Such factors may be updated from ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 Aziyo Biologics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4790334 (State or other jurisdiction of ( ...

Aziyo Biologics, Inc. (AZYO) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is bei ...